Celcuity (CELC) Target Price Raised Due to Trial Data Strength

AI Summary

Stifel has increased the price target for Celcuity (CELC) due to positive trial data. This adjustment reflects confidence in the company's ongoing developments, which may significantly influence market perception. The new target showcases the firm's belief in the potential of Celcuity's products in the competitive biotech landscape. If the trial data continues to support efficacy, it could lead to an uptick in stock performance for Celcuity.